Imran Ahmad, MD, outlines the diagnosis and management of diabetic macular edema, emphasizing screening gaps, socioeconomic barriers, and treatment options in developing countries. He reviews evidence-based protocols, the role of anti-VEGF therapies like aflibercept, ranibizumab, and off-label bevacizumab, and how treatment choices shift when affordability and access are limited.
Sean Adrean, MD, Retina Consultants of Orange County, describes results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of baseline visual acuity…
Omar Krad, MD, shares his practical approach to cataract surgery in patients with wet macular degeneration. This case involves a diabetic, hyperopic patient with vision limited to counting…
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when long-term high blood sugar damages retinal blood vessels, causing them…
Anti-VEGF injections are a common treatment for wet age-related macular degeneration (AMD), aimed at preserving or even improving vision by stopping abnormal blood vessel growth under the macula.…
Deepak Sambhara, MD, Eye Clinic of Wisconsin, discusses results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of central retinal thickness on…
Charles C. Wykoff, MD, highlights both the success and the limitations of current treatments for wet AMD. While anti-VEGF therapies are effective at controlling bleeding and leakage in…
Kenneth C. Fan, MD, MBA, Retinal Consultants of Texas, discusses how increased doses of aflibercept can be used to treat patients with wet age-related macular degeneration and diabetic…
In an interview conducted at the Association for Research in Vision and Ophthalmology Annual Meeting, May 5-9, 2023, Jordana Fein, MD, MS, Retina Group of Washington Fairfax, Virginia,…
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
